TYBR Health marked the first U.S. clinical use of the B3 GEL System. The initial case was a complex second-stage flexor tendon reconstruction.
B3 GEL is a collagen-based tissue protector derived from extracellular matrix (ECM). Unlike physical barriers, B3 GEL is flowable and conforms to the tissue surface, maintaining biomechanical separation during the critical healing window before being naturally resorbed.
TYBR Health continues to evaluate the clinical performance of the system through postmarket surveillance and real-world clinical use.
Chris Wright, Chief Commercial Officer of TYBR Health, said, “These initial procedures mark the transition from regulatory clearance to real-world clinical application, allowing surgeons to directly address post-surgical tissue tethering—a complication that too often limits patient mobility and extends recovery times. By protecting healing tissues during the critical early phase, B3 GEL helps bridge the gap between surgical repair and functional success, enabling patients to regain movement faster and more completely. We’re excited to see these early outcomes that support our mission of improving quality of life for millions affected by tendon, ligament, and muscle procedures.”
TYBR Health marked the first U.S. clinical use of the B3 GEL System. The initial case was a complex second-stage flexor tendon reconstruction.
B3 GEL is a collagen-based tissue protector derived from extracellular matrix (ECM). Unlike physical barriers, B3 GEL is flowable and conforms to the tissue surface, maintaining biomechanical separation...
TYBR Health marked the first U.S. clinical use of the B3 GEL System. The initial case was a complex second-stage flexor tendon reconstruction.
B3 GEL is a collagen-based tissue protector derived from extracellular matrix (ECM). Unlike physical barriers, B3 GEL is flowable and conforms to the tissue surface, maintaining biomechanical separation during the critical healing window before being naturally resorbed.
TYBR Health continues to evaluate the clinical performance of the system through postmarket surveillance and real-world clinical use.
Chris Wright, Chief Commercial Officer of TYBR Health, said, “These initial procedures mark the transition from regulatory clearance to real-world clinical application, allowing surgeons to directly address post-surgical tissue tethering—a complication that too often limits patient mobility and extends recovery times. By protecting healing tissues during the critical early phase, B3 GEL helps bridge the gap between surgical repair and functional success, enabling patients to regain movement faster and more completely. We’re excited to see these early outcomes that support our mission of improving quality of life for millions affected by tendon, ligament, and muscle procedures.”
Copy to clipboard 
